CVS Health Corporation has outperformed its industry peers by effectively managing challenges and executing strategic plans. The company reported better-than-expected results for Q1 and raised its outlook, anticipating margin expansion by 2026 and projecting low double-digit returns for investors. While its Health Services and Insurance segments are expected to grow moderately, the retail segment may decline gradually but with improved margins. Trading at $105, CVS is priced above its historical average but remains cheaper than competitors, supporting a continued 'Buy' rating.

More News (CVS)

CVS Health to report Q2 2026 earnings on August 5 with live webcast for investors.

CVS Health announced it will hold a conference call on August 5, 2026, at 8:00 a.m. ET to discuss its second quarter financial results. The event will be webcast live on the company's investor relations website and archived for one year. CVS Health o...

Company Fundamentals

Neutral

2 days ago

CVS Health beats Q1 expectations, expects margin growth and strong investor returns by 2026

More News (CVS)

CVS Health to report Q2 2026 earnings on August 5 with live webcast for investors.

Invest & Trade with
#1 Award-Winning Investment Super App

Invest

Features

Fees

Learn

Investment Clubs (Coming Soon)

Support

iOS App Store

Google Play Store

CVS Health beats Q1 expectations, expects margin growth and strong investor returns by 2026

More News (CVS)

CVS Health to report Q2 2026 earnings on August 5 with live webcast for investors.

Invest & Trade with#1 Award-Winning Investment Super App

iOS App Store

Google Play Store

Invest & Trade with
#1 Award-Winning Investment Super App